ClinicalTrials.gg
CompletedNCT00472420Updated Aug 15, 2017Results posted

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

A Phase 2 interventional study of rituximab [MabThera/Rituxan] and First line chemotherapy in Mantle Cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 7 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 157 studies testing rituximab in Lymphoma, Mantle-Cell — 12 open to participants now, 30 under way, 3 of them phase 3. Rituximab · Lymphoma, Mantle-Cell.

Enrollment
59th of 153
48 · median 37
Started
2007
with 5 others
Phase 2
92 of 157
9 open now
Registered
61st of 157
by date

Among the 157 studies testing rituximab in Lymphoma, Mantle-Cell, this one is the 59th largest by enrollment of the 153 interventional ones that give a count, is one of 6 that started in 2007, is one of 92 in phase 2, and was the 61st registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

12 of the 157 studies testing rituximab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies testing rituximab in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This single arm study will evaluate the benefit of adding MabThera to standard induction chemotherapy in patients with newly diagnosed mantle cell lymphoma. The safety and tolerability of a MabThera-containing first line regimen will also be assessed. All patients will receive MabThera (375mg/m2 iv) every 3 weeks for 8 cycles, in combination with standard chemotherapy. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven mantle cell lymphoma;
  • previously untreated disease at stage II, III and IV, requiring therapy.

Exclusion criteria

Exclusion Criteria:

  • known reaction to rituximab, or known anti-murine antibody reactivity or known hypersensitivity to murine antibodies;
  • active other than mantle cell lymphoma within 5 years of start of study, with the exception of resected basal cell cancer, squamous cell cancer of the skin, or in situ cancer of the cervix;
  • serious disorders interfering with full standard dosing chemotherapy;
  • stage I disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan] · Drug: First line chemotherapy

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    375mg/m2 iv every 3 weeks

  • DrugFirst line chemotherapy

    As prescribed

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR)

    CR was defined by: a) disappearance of clinical/radiographic evidence of disease, disease-related symptoms, and biochemical abnormalities; b) decrease in lymph nodes (LNs) greater than (\>) 1.5 centimeters (cm) in greatest transverse diameter (GTD) to less than (\<) 1.5 cm, a decrease in LNs 1.1 - 1.5 cm to 1 cm or 75 percent (%) decrease in sum of the products of GTD (SPD); c) non-palpable spleen, decreased size of enlarged organs, and disappearance of nodules; and d) disappearance of bone marrow (BM) infiltrate. CR(u) was defined as fulfilling a) and c), above, with greater than or equal to (≥) 1 of the following: a) \> 75% decrease in SPD of LNs \> 1.5 cm, and \> 75% decrease in SPD of previously confluent LNs; b) indeterminate BM, or c) confirmed CR. PR was defined by: a) 50% decrease in SPD of the 6 largest LNs; b) no increase in LNs, liver, or spleen size; c) ≥ 50% decrease in splenic and hepatic nodule SPDs; d) no measurable disease in other organs; and e) no new sites of disease.

    Time frame: Screening, Baseline (BL), every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the median time, in months, from the date of study entry to disease progression, death due to mantle cell lymphoma, or last contact. Progressive disease (PD) was defined by: a) 50% increase from nadir in the SPD of any previously identified abnormal LN, or b) appearance of any new lesion during or at the end of treatment. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.

    Time frame: Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)

  2. Event Free Survival (EFS)

    EFS was defined as the median time, in months, from the date of study entry disease progression, relapse, secondary malignancy, death or last contact. Relapse was defined by: a) appearance of any new lesion or a ≥ 50% increase in size of previously involved sites, or b) ≥ 50% increase in GTD of any previously identified LN \>1 cm in short axis or in the SPD of more than one LN. The 95% CI was estimated using Kaplan-Meier methodology.

    Time frame: Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)

07

Results

Posted Nov 26, 2014

Participant flow

Induction Treatment Period
Participant flow — Induction Treatment Period
MilestoneRituximab Plus (+) Chemotherapy
Started48
Completed32
Not completed16
Withdrew: Physician decision9
Withdrew: Adverse event3
Withdrew: Non-compliance1
Withdrew: Death3
Follow-up Period
Participant flow — Follow-up Period
MilestoneRituximab Plus (+) Chemotherapy
Started32
Completed15
Not completed17
Withdrew: Death5
Withdrew: Physician decision9
Withdrew: Lost to follow-up2
Withdrew: Protocol violation1

Outcome measures

PrimaryNumber of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR)

CR was defined by: a) disappearance of clinical/radiographic evidence of disease, disease-related symptoms, and biochemical abnormalities; b) decrease in lymph nodes (LNs) greater than (\>) 1.5 centimeters (cm) in greatest transverse diameter (GTD) to less than (\<) 1.5 cm, a decrease in LNs 1.1 - 1.5 cm to 1 cm or 75 percent (%) decrease in sum of the products of GTD (SPD); c) non-palpable spleen, decreased size of enlarged organs, and disappearance of nodules; and d) disappearance of bone marrow (BM) infiltrate. CR(u) was defined as fulfilling a) and c), above, with greater than or equal to (≥) 1 of the following: a) \> 75% decrease in SPD of LNs \> 1.5 cm, and \> 75% decrease in SPD of previously confluent LNs; b) indeterminate BM, or c) confirmed CR. PR was defined by: a) 50% decrease in SPD of the 6 largest LNs; b) no increase in LNs, liver, or spleen size; c) ≥ 50% decrease in splenic and hepatic nodule SPDs; d) no measurable disease in other organs; and e) no new sites of disease.

Time frame:
Screening, Baseline (BL), every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
Reported as:
Number · participants
Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR)
participantsRituximab + Chemotherapy
CR19
PR8
SecondaryProgression Free Survival (PFS)

PFS was defined as the median time, in months, from the date of study entry to disease progression, death due to mantle cell lymphoma, or last contact. Progressive disease (PD) was defined by: a) 50% increase from nadir in the SPD of any previously identified abnormal LN, or b) appearance of any new lesion during or at the end of treatment. The 95% confidence interval (CI) was estimated using Kaplan-Meier methodology.

Time frame:
Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsRituximab + Chemotherapy
Progression Free Survival (PFS)30.456 (19.011 to 41.901)
SecondaryEvent Free Survival (EFS)

EFS was defined as the median time, in months, from the date of study entry disease progression, relapse, secondary malignancy, death or last contact. Relapse was defined by: a) appearance of any new lesion or a ≥ 50% increase in size of previously involved sites, or b) ≥ 50% increase in GTD of any previously identified LN \>1 cm in short axis or in the SPD of more than one LN. The 95% CI was estimated using Kaplan-Meier methodology.

Time frame:
Screening, BL, every 21 days thereafter up to Week 27, every 3 months thereafter up to Month 24, Withdrawal Visit (4 weeks after discontinuation of study treatment)
Reported as:
Median · months
Event Free Survival (EFS)
monthsRituximab + Chemotherapy
Event Free Survival (EFS)40.049 (33.296 to 46.802)

Adverse events

Collected over Adverse events (AEs) were recorded throughout the study up to 3 months after the last study drug administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Chemotherapy—25/48 (52.1%)23/48 (47.9%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventRituximab + Chemotherapy
AnaemiaBlood and lymphatic system disorders6/48
ThrombocytopeniaBlood and lymphatic system disorders4/48
PancytopeniaBlood and lymphatic system disorders4/48
PneumoniaInfections and infestations4/48
AgranulocytosisBlood and lymphatic system disorders4/48
PyrexiaGeneral disorders3/48
Febrile neutropeniaBlood and lymphatic system disorders3/48
SepsisInfections and infestations2/48
Deep vein thrombosisVascular disorders2/48
HyperglycaemiaMetabolism and nutrition disorders2/48
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRituximab + Chemotherapy
AgranulocytosisBlood and lymphatic system disorders5/48
ThrombocytopeniaBlood and lymphatic system disorders4/48
ChillsGeneral disorders4/48
PyrexiaGeneral disorders3/48
PancytopeniaBlood and lymphatic system disorders2/48
DiarrhoeaGastrointestinal disorders2/48
PneumoniaInfections and infestations2/48
Diarrhoea infectiousGastrointestinal disorders1/48
BacteremiaBlood and lymphatic system disorders1/48
Herpes zosterInfections and infestations1/48

Baseline characteristics

Intent-to-treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Rituximab + Chemotherapy
Median70.20 (44.46 to 82.31)
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Chemotherapy
Female16
Male32
08

Study locations

7 sites
  • National Institute of Oncology, A Dept of Internal Medicine
    Budapest, 1122, Hungary
  • University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Korhaz; Hematologia
    Gyor, 9024, Hungary
  • Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology
    Kaposvar, 7400, Hungary
  • Miskolci Semmelweis Korhaz; Ii Belgyogyaszat
    Miskolc, 3529, Hungary
  • University of Szeged, II Dept of Internal Medicine
    Szeged, 6720, Hungary
  • Zala Megyei Korhaz; Ii. Belgyogyaszat
    Zalaegerszeg, 8901, Hungary
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in May 2011, 46 months.

Results were first posted in Nov 2014, 3 years 6 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 46 months is close to that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2007
First posted
May 11, 2007
StartActual
Jun 27, 2007
Primary completionActual
May 25, 2011
CompletionActual
May 25, 2011
Results first posted
Nov 26, 2014
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00472420
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 11, 2007
Start date
Jun 27, 2007
Primary completion
May 25, 2011
Completion
May 25, 2011
Results posted
Nov 26, 2014
Last update
Aug 15, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion